Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

Literature DB >> 27866633

Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

Thanyanan Reungwetwattana¹, Alex A Adjei².

Abstract

Entities: Disease

Mesh：

Year: 2016 PMID： 27866633 DOI： 10.1016/j.jtho.2016.10.008

Source DB: PubMed Journal: J Thorac Oncol ISSN： 1556-0864 Impact factor: 15.609

Keyword Cloud
Cited

× No keyword cloud information.

16 in total

1. Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.

Authors: Gregory R Stroh; Tobias Peikert; Patricio Escalante
Journal: Cancer Immunol Immunother Date: 2021-03-26 Impact factor: 6.968

Review 2. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.

Authors: Karthik Suresh; Jarushka Naidoo; Cheng Ting Lin; Sonye Danoff
Journal: Chest Date: 2018-09-04 Impact factor: 9.410

3. Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators.

Authors: Takafumi Yamaya; Hwang Moon Hee; Takayuki Aoyagi; Tatsuya Ogimoto; Naoki Yamada; Ryoichi Ishikawa; Erika Nakai; Kenta Nishi; Chie Yoshimura; Yasuo Nishizaka
Journal: Respir Med Case Rep Date: 2019-05-27

4. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.

Authors: Catherine R Sears; Tobias Peikert; Jennifer D Possick; Jarushka Naidoo; Mizuki Nishino; Sandip P Patel; Philippe Camus; Mina Gaga; Edward B Garon; Michael K Gould; Andrew H Limper; Philippe R Montgrain; William D Travis; M Patricia Rivera
Journal: Am J Respir Crit Care Med Date: 2019-09-15 Impact factor: 21.405

5. Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review.

Authors: Ronwyn van Eeden; Bernardo L Rapoport; Teresa Smit; Ronald Anderson
Journal: Front Oncol Date: 2019-07-24 Impact factor: 6.244

Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

1. Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.

Review 2. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.

3. Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators.

4. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.

5. Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review.

6. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.

Review 7. Immune Checkpoint Inhibitors in Special Populations.

8. Are there common threads in the susceptibility to cancer and tuberculosis?

Review 9. Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.

10. Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab.